The field of predictive medicine, one subsector in which the largely faded near-term promise of genomics maintains its color, is just where Myriad Genetics Inc. has wanted to be from the start - but not the only place. (BioWorld Financial Watch)
As Transkaryotic Therapies Inc. revealed a weak hand regarding Replagal (agalsidase alfa), all eyes turned to competitor Genzyme General, which has been playing its cards close to the vest. (Bioworld Today)
About two weeks after filing a shelf registration statement to sell up to $250 million in securities, Myriad Genetics Inc. is raising $57.3 million through a pursuant offering of 3 million shares of stock. (BioWorld Today)
About one month after saying it would suspend recruitment in a Phase III trial of its lead prostate cancer drug, sell some fixed assets and consider other options for the future, Northwest Biotherapeutics Inc. has made more cuts and may shut down entirely. (BioWorld Today)
Study, patience and a kind of indomitable hope: such are the qualities required of the biotechnology investor, and of researchers in the HIV field. (BioWorld Financial Watch)
